Patent · US Active

TGF-beta-specific antibodies and methods of use thereof for treatment

US9714285B2 · kind B2 · utility

3Cited by
53References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 24, 2015
Grant dateJul 25, 2017
Priority date
Expiry dateJul 24, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.